Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Liabilities (2020 - 2026)

RxSight filings provide 6 years of Total Liabilities readings, the most recent being $36.1 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 3.2% to $36.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.1 million, a 3.2% decrease, with the full-year FY2025 number at $36.1 million, down 3.2% from a year prior.
  • Total Liabilities hit $36.1 million in Q4 2025 for RxSight, up from $32.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $301.9 million in Q1 2021 to a low of $19.2 million in Q1 2024.
  • Median Total Liabilities over the past 5 years was $37.7 million (2023), compared with a mean of $54.3 million.
  • Biggest five-year swings in Total Liabilities: tumbled 88.16% in 2021 and later skyrocketed 75.34% in 2025.
  • RxSight's Total Liabilities stood at $54.5 million in 2021, then rose by 10.62% to $60.3 million in 2022, then crashed by 63.18% to $22.2 million in 2023, then soared by 68.22% to $37.3 million in 2024, then decreased by 3.2% to $36.1 million in 2025.
  • The last three reported values for Total Liabilities were $36.1 million (Q4 2025), $32.6 million (Q3 2025), and $31.0 million (Q2 2025) per Business Quant data.